Table 4.
Overview of GWAS studies in COVID-19.
| Type of Research | Number of Participants | Ethnicity | Number of Associations | References |
|---|---|---|---|---|
| Meta-analysis | 835 patients and 1255 controls from Italy and 775 patients and 950 controls from Spain | European | 25 | [129] |
| Meta-analysis | 1457 genotyped (598/859 with severe/mild symptoms) and 1141 sequenced (severe/mild: 474/667) Chinese patients. Further incorporated 1401 genotyped and 948 sequenced ancestry-matched population controls. Genome-wide association was tested on 1072 severe cases versus 3875 mild or population controls, followed by a trans-ethnic meta-analysis with summary statistics of 3199 hospitalized cases and 897,488 population controls from the COVID-19 Host Genetics Initiative |
Chinese | 0 | [130] |
| Original research | 1723 outpatients with at least one risk factor for disease severity from the COLCORONA clinical trial | European | 3 | [132] |
| Original research | 2244 critically ill patients with COVID-19 from 208 UK ICUs | Mixed | 8 | [133] |
| Original research | 1778 infected cases | European | 12 | [134] |
| Meta-analysis | 3288 COVID-19 patients676,840 controls | European | 3 | [135] |
| Meta-analysis | 1,051,032 23 andMe research participants | Mixed | 360 | [136] |
| Meta-analysis | 1678 COVID-19 cases and 674,635 controls | NA | 2 | [137] |
| Initiative | 105 studies | Global initiative | 0 | [139] |
| Original research | 175,977 participants | European | 17 | [138] |
| Original research | COVID-19 phenotypes: 482 hospitalized and 164 non-hospitalized participants | GWAS: Arabic trans-ancestry meta-analysis: European, American, South Asian, and East Asian | 8 | [131] |
ICU: intensive care unit, COLCORONA: Colchicine Coronavirus SARS-CoV2 Trial, NA: not available.